Lyndra Therapeutics president and COO Jessica Ballinger (L) and CMO Rich Scranton
June 9, 2023 07:26 AM EDTUpdated 01:07 PM
Financing
Startups
R&D

Lyn­dra Ther­a­peu­tics eyes $180M Se­ries D for po­ten­tial 2026 launch of once-week­ly schiz­o­phre­nia med

Kyle LaHucik

Senior Reporter

With a Phase III tri­al now un­der­way for a once-week­ly, long-act­ing ver­sion of the an­tipsy­chot­ic med risperi­done, Lyn­dra Ther­a­peu­tics is eye­ing a large Se­ries D …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Roivant brings rare dis­ease pro­gram clos­er as Im­muno­vant CEO re­tires

Chi­na start­up in­jects CRISPR ther­a­py in­to the brain for the first time

FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

Trodelvy and Keytru­da com­bo suc­ceeds in Phase 3 breast can­cer study

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times